HOST MODULATION/PERIODONTAL THERAPY EFFECTS ON DIABETES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是确定药物Periostat是否可以减少I型糖尿病患者的牙周疾病。牙周病会引起牙周炎，并可能导致牙齿脱落。Periostat是一种已被食品和药物管理局批准用于治疗非糖尿病患者牙周病的药物。研究表明，当使用这种药物时，与标准的牙齿和牙根清洁一起使用，非糖尿病患者的牙周病比只进行牙齿和牙根清洁的患者有更大的改善。一旦研究结束，我们应该知道药物Periostat是否对I型糖尿病患者的牙周病和全身炎症有效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine if the drug Periostat will reduce periodontal disease in persons with Type I diabetes. Periodontal disease causes inflammation of the gums and can result in tooth loss. Periostat is a drug that has been approved by the Food and Drug Administration for the use in the treatment of periodontal disease in non-diabetic persons. It has been shown that when the drug is used, along with standard tooth and root cleaning, non-diabetic patients have greater improvement in their gum disease than patients treated only with tooth and root cleaning. Once the study is concluded we should know if the drug Periostat is useful for the treatment of periodontal disease and whole body inflammation in persons with Type I diabetes.